The country’s aging population is driving demand for innovative treatments.
GlobalData said Japan's 10-year government fund supports innovative drug development signals, which suggests a shift toward achieving policy aimed at building a more resilient drug ecosystem.
Currently, as of March 20, Japanese pharmaceutical companies have 62 innovative drugs in the pre-registration stage, 174 in the Phase III clinical trials, 174 in the Phase III clinical trials, and 213 in the Phase II clinical trials.
“Japan has begun reviewing its lengthy regulatory approval process and timing to reduce drug lag and supply shortages to reduce dependence on imported drugs and improve patients' access to critical treatments,” said GlobalData's Pharma Analyst.
The country’s aging population is driving the need for innovative treatments for regenerative medicine, personalized therapies and AI-driven drug discovery.
Meanwhile, the development of digital health technologies and R&D incentives is promoting a dynamic and evolving drug landscape.
Sahu added: “While Japan's initiative is aligned with other Asia-Pacific countries in terms of government support and innovation, it aims to address its unique challenges, including drug lag and pricing reforms.”
